Journal Article

Autosomal dominant polycystic kidney disease—the patient on renal replacement therapy

M. Zeier, Elisabeth Jones and E. Ritz

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 11, issue supp6, pages 18-20
Published in print January 1996 | ISSN: 0931-0509
e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/11.supp6.18
Autosomal dominant polycystic kidney disease—the patient on renal replacement therapy

Show Summary Details

Preview

In Europe ∼6% of all patients on chronic renal replacement therapy suffer from polycystic kidney disease. Survival of patients with polycystic kidney disease on renal replacement therapy is better than for other primary renal diseases, despite a similar cardiovascular risk profile. We documented a significantly higher erythropoietin level in polycystic patients even inadvanced uraemia and on dialysis. A better haemoglobin level seems to improve long-term survival because of a possible beneficial effect on cardiac function. There is no increased risk of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease. Polycystic patients on dialysis should be followed for cardiac valve abnormalities and cerebral aneurysms.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.